[{"id":"f5ce8c06-3250-40ff-b25a-dd3430d92b46","acronym":"","url":"https://clinicaltrials.gov/study/NCT07078604","created_at":"2025-07-26T13:31:46.938Z","updated_at":"2025-07-26T13:31:46.938Z","phase":"Phase 2","brief_title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT07078604","lead_sponsor":"University of Washington","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-07-22"},{"id":"913a7f90-f43b-43fc-9a5c-45399bce2739","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907475","created_at":"2021-01-18T19:14:04.518Z","updated_at":"2025-02-25T13:39:50.577Z","phase":"Phase 2","brief_title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)","source_id_and_acronym":"NCT03907475","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD4 • IL2","pipe":"","alterations":" ","tags":["TMB • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"424f1715-a08a-4e86-a255-1bc30e3c69e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03203525","created_at":"2021-01-18T15:47:47.088Z","updated_at":"2025-02-25T15:42:56.837Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","source_id_and_acronym":"NCT03203525","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • temsirolimus • pegylated liposomal doxorubicin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-10"},{"id":"79754c99-3751-46a3-9cbb-21442fd0c3e5","acronym":"NRG-GY023","url":"https://clinicaltrials.gov/study/NCT04739800","created_at":"2021-02-05T13:56:26.400Z","updated_at":"2025-02-25T15:26:41.757Z","phase":"Phase 2","brief_title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","source_id_and_acronym":"NCT04739800 - NRG-GY023","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["PD-L1 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/10/2021","start_date":" 06/10/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 06/14/2025","study_completion_date":" 06/14/2025","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"a3c29634-7fe3-458b-95a0-a95c7ed454c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101788","created_at":"2021-01-18T09:42:39.713Z","updated_at":"2025-02-25T16:36:20.602Z","phase":"Phase 2/3","brief_title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02101788","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 02/27/2014","start_date":" 02/27/2014","primary_txt":" Primary completion: 04/04/2019","primary_completion_date":" 04/04/2019","study_txt":" Completion: 10/11/2025","study_completion_date":" 10/11/2025","last_update_posted":"2025-02-06"},{"id":"6a7e2afb-013b-43d3-b31e-6052a197be35","acronym":"met-HEReMYTA","url":"https://clinicaltrials.gov/study/NCT02488564","created_at":"2021-01-18T11:59:22.933Z","updated_at":"2025-02-25T16:58:50.319Z","phase":"Phase 2","brief_title":"A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer","source_id_and_acronym":"NCT02488564 - met-HEReMYTA","lead_sponsor":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • metformin • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 12/17/2014","start_date":" 12/17/2014","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 03/17/2020","study_completion_date":" 03/17/2020","last_update_posted":"2025-02-03"},{"id":"caa0f388-4c19-438d-9bce-36b37f87c82f","acronym":"NRG-GY004","url":"https://clinicaltrials.gov/study/NCT02446600","created_at":"2021-01-18T11:43:37.532Z","updated_at":"2025-02-25T15:06:35.061Z","phase":"Phase 3","brief_title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02446600 - NRG-GY004","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 579","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 02/23/2020","primary_completion_date":" 02/23/2020","study_txt":" Completion: 08/23/2025","study_completion_date":" 08/23/2025","last_update_posted":"2025-02-03"},{"id":"4c69c646-417d-429d-bb95-ea9731d61b06","acronym":"COCOS","url":"https://clinicaltrials.gov/study/NCT02502266","created_at":"2021-01-18T12:04:33.243Z","updated_at":"2024-07-02T16:35:02.420Z","phase":"Phase 2/3","brief_title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","source_id_and_acronym":"NCT02502266 - COCOS","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 562","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-21"},{"id":"fb234759-a38a-4cfe-bab9-0b45c1624c62","acronym":"","url":"https://clinicaltrials.gov/study/NCT00712881","created_at":"2021-01-18T02:40:06.317Z","updated_at":"2024-07-02T16:35:17.976Z","phase":"Phase 2","brief_title":"Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer","source_id_and_acronym":"NCT00712881","lead_sponsor":"Cephalon, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • cyclophosphamide • Myocet (non-pegylated liposomal doxorubicin)"],"overall_status":"Completed","enrollment":" Enrollment 126","initiation":"Initiation: 10/13/2008","start_date":" 10/13/2008","primary_txt":" Primary completion: 09/17/2015","primary_completion_date":" 09/17/2015","study_txt":" Completion: 09/17/2015","study_completion_date":" 09/17/2015","last_update_posted":"2024-02-23"},{"id":"8e2f554f-5b71-4b80-85eb-7d4289eed34a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02456857","created_at":"2021-01-18T11:47:13.758Z","updated_at":"2024-07-02T16:35:19.566Z","phase":"Phase 2","brief_title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","source_id_and_acronym":"NCT02456857","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR • VIM","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR • VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • pegylated liposomal doxorubicin • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 01/12/2016","start_date":" 01/12/2016","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-02-13"},{"id":"0b6d7e60-5588-4d27-b84f-436660d0c1bd","acronym":"NRG-GY009","url":"https://clinicaltrials.gov/study/NCT02839707","created_at":"2021-01-18T13:56:21.115Z","updated_at":"2024-07-02T16:35:29.911Z","phase":"Phase 2/3","brief_title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02839707 - NRG-GY009","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 443","initiation":"Initiation: 06/23/2017","start_date":" 06/23/2017","primary_txt":" Primary completion: 05/09/2023","primary_completion_date":" 05/09/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2023-11-08"},{"id":"49297bcc-58c4-446b-9d67-218005819ada","acronym":"NRG-GY029","url":"https://clinicaltrials.gov/study/NCT05295589","created_at":"2022-03-26T01:54:07.007Z","updated_at":"2024-07-02T16:35:35.787Z","phase":"Phase 2","brief_title":"Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy","source_id_and_acronym":"NCT05295589 - NRG-GY029","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • MUC16","pipe":" | ","alterations":" BRCA2 mutation • HRD","tags":["BRCA1 • BRCA2 • HRD • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • Aliqopa (copanlisib) • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 03/17/2023","primary_completion_date":" 03/17/2023","study_txt":" Completion: 03/17/2023","study_completion_date":" 03/17/2023","last_update_posted":"2023-09-26"},{"id":"3ca2db9e-3976-48ee-b980-c04bbac2ace6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02214381","created_at":"2021-01-18T10:22:33.060Z","updated_at":"2024-07-02T16:35:52.491Z","phase":"Phase 3","brief_title":"A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response","source_id_and_acronym":"NCT02214381","lead_sponsor":"West German Study Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Myocet (non-pegylated liposomal doxorubicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-03-24"},{"id":"9afcb6f4-d096-4d87-9778-bc395948cfef","acronym":"","url":"https://clinicaltrials.gov/study/NCT00129896","created_at":"2021-02-22T06:52:09.236Z","updated_at":"2024-07-02T16:35:54.048Z","phase":"Phase 1/2","brief_title":"Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients","source_id_and_acronym":"NCT00129896","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • doxorubicin hydrochloride • Myocet (non-pegylated liposomal doxorubicin) • AP06 (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 01/01/2004","start_date":" 01/01/2004","primary_txt":" Primary completion: 12/01/2008","primary_completion_date":" 12/01/2008","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2023-03-06"},{"id":"f06a832d-d2a3-4a7a-b5f8-c7c8ac07899b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03301350","created_at":"2021-01-18T16:18:33.231Z","updated_at":"2024-07-02T16:35:56.631Z","phase":"Phase 2","brief_title":"Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer","source_id_and_acronym":"NCT03301350","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/07/2017","start_date":" 11/07/2017","primary_txt":" Primary completion: 03/23/2020","primary_completion_date":" 03/23/2020","study_txt":" Completion: 02/07/2022","study_completion_date":" 02/07/2022","last_update_posted":"2023-02-01"},{"id":"33578df7-b78c-4725-a1f1-543aa6b751b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02562378","created_at":"2021-01-17T17:13:15.683Z","updated_at":"2024-07-02T16:36:16.762Z","phase":"Phase 1","brief_title":"T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT02562378","lead_sponsor":"MedSIR","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2022-02-23"},{"id":"7c2ec8d1-6839-4c57-b0f1-54acd77acd17","acronym":"Stop\u0026Go","url":"https://clinicaltrials.gov/study/NCT01935492","created_at":"2021-01-18T08:45:17.036Z","updated_at":"2024-07-02T16:36:51.167Z","phase":"Phase 3","brief_title":"8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer","source_id_and_acronym":"NCT01935492 - Stop\u0026Go","lead_sponsor":"Borstkanker Onderzoek Groep","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • capecitabine • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 420","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2020-01-18"},{"id":"5b6f24f6-2023-4283-9d41-68b0a317d531","acronym":"","url":"https://clinicaltrials.gov/study/NCT00088855","created_at":"2021-01-18T00:15:49.272Z","updated_at":"2024-07-02T16:36:55.332Z","phase":"Phase 2","brief_title":"Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma","source_id_and_acronym":"NCT00088855","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 06/15/2004","start_date":" 06/15/2004","primary_txt":" Primary completion: 10/31/2006","primary_completion_date":" 10/31/2006","study_txt":" Completion: 01/08/2008","study_completion_date":" 01/08/2008","last_update_posted":"2019-09-23"},{"id":"4fa940f3-a63f-4227-ad01-cfd842aedbbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01459380","created_at":"2021-01-18T06:03:56.828Z","updated_at":"2024-07-02T16:36:57.890Z","phase":"Phase 1","brief_title":"Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","source_id_and_acronym":"NCT01459380","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • MUC16","pipe":"","alterations":" ","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • veliparib (ABT-888) • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 10/11/2011","start_date":" 10/11/2011","primary_txt":" Primary completion: 06/08/2016","primary_completion_date":" 06/08/2016","study_txt":" Completion: 02/11/2017","study_completion_date":" 02/11/2017","last_update_posted":"2019-07-22"},{"id":"c91160a6-9978-4e56-82c6-da599bd87237","acronym":"","url":"https://clinicaltrials.gov/study/NCT01489371","created_at":"2021-01-18T06:13:44.198Z","updated_at":"2024-07-02T16:37:02.018Z","phase":"Phase 1","brief_title":"EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT01489371","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 07/09/2012","start_date":" 07/09/2012","primary_txt":" Primary completion: 12/30/2014","primary_completion_date":" 12/30/2014","study_txt":" Completion: 01/27/2018","study_completion_date":" 01/27/2018","last_update_posted":"2019-03-12"},{"id":"bdc04392-7fea-44b3-8c55-36b4fe355a8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01145430","created_at":"2021-01-18T04:33:29.572Z","updated_at":"2024-07-02T16:37:15.344Z","phase":"Phase 1","brief_title":"Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer","source_id_and_acronym":"NCT01145430","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 05/23/2017","primary_completion_date":" 05/23/2017","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-22"},{"id":"6261ea7c-5de1-4381-9330-e747462e7ac0","acronym":"SOLTI-Opti-HER","url":"https://clinicaltrials.gov/study/NCT01669239","created_at":"2021-01-18T07:13:12.270Z","updated_at":"2025-02-25T14:00:05.762Z","phase":"Phase 2","brief_title":"Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer","source_id_and_acronym":"NCT01669239 - SOLTI-Opti-HER","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 83","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-11-06"},{"id":"131825b5-f2d5-4147-9680-3719eface49a","acronym":"GeparOcto","url":"https://clinicaltrials.gov/study/NCT02125344","created_at":"2021-01-18T09:50:50.151Z","updated_at":"2025-02-25T14:00:27.083Z","phase":"Phase 3","brief_title":"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)","source_id_and_acronym":"NCT02125344 - GeparOcto","lead_sponsor":"German Breast Group","biomarkers":" HER-2 • ER • PIK3CA • PGR • CD80","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PIK3CA mutation • ER negative","tags":["HER-2 • ER • PIK3CA • PGR • CD80"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PIK3CA mutation • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 961","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 01/30/2017","study_completion_date":" 01/30/2017","last_update_posted":"2017-07-13"}]